England Uses Gene Therapy to Treat Hunter Syndrome
- A three-year-old boy in the United Kingdom has received the world's first stem cell gene therapy for Hunter syndrome, a rare and devastating genetic disorder.
- Hunter syndrome, also known as mucopolysaccharidosis II (MPS II), is a rare genetic disorder caused by a deficiency in the enzyme iduronate-2-sulfatase. This deficiency leads to the buildup...
- The pioneering treatment was developed by researchers at the university of Manchester and administered at the Royal Manchester Children's Hospital (RMCH).
World-First Gene Therapy Treats Hunter Syndrome in Young Boy
Table of Contents
A three-year-old boy in the United Kingdom has received the world’s first stem cell gene therapy for Hunter syndrome, a rare and devastating genetic disorder. The treatment, developed over a decade, offers potential for a cure and a important alternative to lifelong, expensive enzyme replacement therapy.
Understanding Hunter Syndrome
Hunter syndrome, also known as mucopolysaccharidosis II (MPS II), is a rare genetic disorder caused by a deficiency in the enzyme iduronate-2-sulfatase. This deficiency leads to the buildup of complex sugars in the body’s cells, causing progressive damage to organs and the brain. The Mayo Clinic reports that symptoms typically appear between ages 2 and 4, and the average life expectancy is between 10 and 20 years.
Breakthrough Gene therapy Treatment
The pioneering treatment was developed by researchers at the university of Manchester and administered at the Royal Manchester Children’s Hospital (RMCH). The boy received the single-dose gene therapy in febuary 2025, and has shown continued recovery in the months following the procedure. Interesting Engineering details the process.
The therapy utilizes the patient’s own stem cells, which are genetically modified in a laboratory to correct the faulty gene responsible for the enzyme deficiency. These corrected stem cells are then reintroduced into the patient’s body, where they begin to produce the missing enzyme, breaking down accumulated toxic sugars in the brain.
Researchers hope this treatment will not only address the symptoms of Hunter syndrome but also prevent long-term complications like dementia and perhaps offer a complete cure.
Cost-Effectiveness and Future Implications
Currently, the standard treatment for Hunter syndrome is enzyme replacement therapy, which requires weekly infusions for life and carries a substantial cost of approximately £375,000 (approximately $475,000 USD as of December 12, 2025) per year. This new stem cell gene therapy offers a potentially more effective and cost-efficient alternative.
while still early, the success of this trial paves the way for further research and potential gene therapies for other genetic disorders.